Acadia takeover could be worth $940M

Acadia Pharmaceuticals, which develops treatments for central nervous system disorders, has acquired CerSci Therapeutics, a clinical-stage biotech company based in Dallas that's researching treatments for chronic pain and other neurological conditions. Acadia paid $52.5 million up front for all outstanding shares of CerSci, with the potential for up to $887 million in additional compensation based on certain milestones.

View details

News & Analysis

Related content